COVID-19 vaccination and long COVID-19

Document Type : Original article

Authors

1 Department of Internal Medicine, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.

2 Department of Radiology, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran

Abstract

According to the literature, COVID-19 vaccines reduce long COVID-19 symptoms such as cognitive dysfunction, kidney diseases, myalgia, and sleeping disorders (5-7). Therefore, the results of the meta-analysis support the clinical safety and efficacy of SARS-CoV-2 vaccines against long COVID-19. However, the available studies have several limitations: 1) there were individuals that exhibited natural improvement of long COVID-19 symptoms which may have been underestimated as vaccination in clinical setting; 2) studies used wide range of COVID-19 vaccines including both inactivated vaccines and mRNA COVID-19 vaccines. Thus, findings should be interpreted with caution. Since booster vaccines show great promise in both prevention of infection and progression, further research on boosters and omicron-specific vaccination is needed to be performed. Consequently, the current comprehensive literature recommends SARS-CoV-2 vaccine to reduce the risk of long COVID-19 in cases of progression. There are no findings of a negative effect of COVID-19 vaccination on worsening symptoms of COVID-19. Therefore, SARS-CoV-2 vaccination should be improved as soon as possible, especially offering a full course of vaccination. More research is needed to discover the mechanism of action of the COVID-19 vaccines on long COVID-19 in the future.

Keywords

References

  1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-46. doi:1038/s41579-022-00846-2 [PMid:36639608]
  2. Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nature Reviews Immunology. 2023;23(10):618-34.
    doi:1038/s41577-023-00904-7
  3. Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, et al. Long COVID science, research and policy. Nature Medicine. 2024:1-17. doi: 1038/s41591-024-03173-6 [PMid:39122965]
  4. Greenhalgh T, Sivan M, Perlowski A, Nikolich JŽ. Long COVID: a clinical update. The Lancet. 2024;404(10453):707-24. doi:1016/S0140-6736(24)01136-X [PMid:39096925]
  5. Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. International Journal of Environmental Research and Public Health. 2022;19(19):12422. doi:3390/ijerph191912422 [PMid:36231717]
  6. Ceban F, Kulzhabayeva D, Rodrigues NB, Di Vincenzo JD, Gill H, Subramaniapillai M, et al. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain, behavior, and immunity. 2023;111:211-29.doi:1016/j.bbi.2023.03.022 [PMid:36990297]
  7. Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41(11):1783-90. doi:10.1016/j.vaccine.2023.02.008 [PMid:36774332]
Reviews in Clinical Medicine
Volume 12, Issue 1
March 2025
Pages 32-33

Files

Share

How to cite

Statistics